Alexion Pharmaceuticals (ALXN) 188.19 $ALXN
Forget Google: 5 Top Stocks With Earnings Thursday
at Investor's Business Daily - Wed Apr 22, 6:31PM CDT
Tech titan Google (GOOGL) will make headlines with its quarterly earnings after the close on Thursday. But Google's growth is sluggish and the stock is lackluster. Check out these five stocks with better performance than the search giant, including...
AMZN: 389.80 (-1.38), PCYC: 256.98 (-0.77), MO: 52.12 (+0.02), ALK: 64.31 (-0.62), LUV: 42.85 (-0.18), SBUX: 48.33 (-0.04), GILD: 104.18 (-1.02), ALXN: 188.19 (+1.41), GM: 37.16 (unch), GOOGL: 549.18 (+6.26), ABBV: 64.52 (+0.91), PG: 83.09 (+0.01), MSFT: 42.99 (+0.36), DOW: 50.02 (+0.37)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 4:30PM CDT
CAM: 49.02 (+0.36), BBT: 38.87 (+0.21), LAZ: 56.56 (-0.08), JAH: 51.68 (-0.16), ASPS: 18.07 (+1.32), HSY: 98.33 (+0.31), CAB: 53.76 (-0.12), CFX: 48.68 (+0.12), FAF: 36.74 (+0.57), HP: 73.53 (+1.48), KKR: 23.37 (+0.21), AEP: 56.14 (+0.17), DNKN: 47.72 (+0.21), CLFD: 15.63 (+0.19), DAN: 21.57 (+0.18), ABBV: 64.52 (+0.91), CSL: 94.86 (+0.78), CAT: 84.87 (+0.95), BHE: 24.51 (-0.19), AVT: 45.49 (+0.28), IR: 67.49 (+0.29), COR: 48.82 (-0.57), ALK: 64.31 (-0.62), COL: 96.55 (+0.45), BKU: 33.64 (+0.12), BCC: 38.42 (-0.13), MJN: 98.92 (-1.00), IQNT: 18.03 (+0.28), ERIC: 12.70 (-0.09), DGX: 76.29 (+0.08), ALXN: 188.19 (+1.41), DOW: 50.02 (+0.37), DST: 116.35 (+0.44), MDP: 52.99 (-0.41), MMM: 164.67 (+0.67), GRA: 97.10 (+0.03), FCX: 20.57 (+0.34), CLI: 18.28 (-0.01), DHR: 85.25 (+0.05), FNB: 13.21 (+0.10), LUV: 42.85 (-0.18), DPS: 78.81 (-0.38), IVC: 19.80 (+0.24), GMT: 59.92 (+0.42), JNS: 17.93 (unch), DPZ: 99.80 (+0.40), DLX: 69.57 (+0.47), CMS: 35.07 (+0.15), LTM: 71.60 (+0.17), MDSO: 47.66 (+0.43), LLY: 72.30 (+0.09), BMS: 44.00 (+0.09), EQT: 87.29 (+0.85), MHO: 23.74 (-0.25), BTU: 4.87 (+0.06), GPK: 14.24 (+0.15), BAX: 70.38 (+0.33), EQM: 83.89 (+0.08), BEAV: 63.43 (-0.01), GM: 37.16 (unch), HUB.B: 110.19 (-0.19), JCI: 51.33 (+0.30)
Alexion reports tomorrow
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:18AM CDT
ALXN: 188.19 (+1.41)
Will Alexion's (ALXN) Soliris Drive Q1 Earnings Beat? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 4:10PM CDT
Alexion Pharmaceuticals, Inc. is scheduled to report first-quarter 2015 earnings results on Apr 23 before the opening bell.
BIIB: 423.57 (+1.46), IMGN: 9.96 (+0.01), ALXN: 188.19 (+1.41), ABBV: 64.52 (+0.91)
Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019 with Alexion Pharmaceuticals, Amgen, Celgene, F. Hoffmann- La Roche, GlaxoSmithKline & Incyte Dominating
PR Newswire Europe - Mon Apr 20, 10:13AM CDT
DUBLIN, Apr. 20, 2015 /PRNewswire/ --Research and Markets
ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), CELGZ: 2.87 (+0.04)
Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
M2 - Mon Apr 20, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w97ksb/global_acquired) has announced the addition of the "Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019" report to their offering. The Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29% over the period 2014-2019 Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS. Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price. According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups. Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population. Key Vendors - Alexion Pharmaceuticals - Amgen - Celgene - F. Hoffmann- La Roche - GlaxoSmithKline - Incyte Other Prominent Vendors - Cyclacel Pharmaceuticals - CTI Biopharma (Cell Therapeutics) - Eli Lilly - Gilead Sciences - Onconova Therapeutics - MebVax Therapeutics - Novartis - Sanofi - Shire Pharmaceuticals - S* Bio Pte For more information visit http://www.researchandmarkets.com/research/w9...l_acquired
CYCC: 0.94 (-0.03), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), ONTX: 2.48 (-0.05), LLY: 72.30 (+0.09), GSK: 46.57 (-0.67), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
Next Week In Biotech: Amgen, AbbVie, Biogen Earnings, UniQure CHMP, AAN Meeting
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
ABT: 48.35 (+1.23), BIIB: 423.57 (+1.46), NEO: 4.84 (-0.03), SGMO: 14.37 (-0.03), IMGN: 9.96 (+0.01), AMGN: 169.10 (+0.64), ILMN: 190.04 (-9.27), SVA: 5.06 (+0.10), BCLI: 4.29 (-0.09), ISRG: 516.93 (-29.80), BABY: 41.64 (+1.71), QURE: 26.15 (-1.44), NURO: 1.32 (-0.02), ABAX: 63.25 (-0.09), GWPH: 113.04 (-0.05), ALXN: 188.19 (+1.41), ABBV: 64.52 (+0.91), AMAG: 57.68 (+0.47), CAT: 84.87 (+0.95), MAA: 76.57 (+1.00), NVS: 103.45 (-0.62)
Top 50 Big Biotech Partnering and M&A Deal Trends Report 2015
M2 - Thu Apr 16, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxqgzt/top_50_big) has announced the addition of the "Top 50 Big Biotech Partnering and M&A Deal Trends" report to their offering. The Top 50 Big Biotech Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies. Top 50 Big Biotech Partnering and M&A Deal Trends provides the user with the following key benefits: - Detailed partnering activity profiles for each of the top 50 big biotech companies - Over 300 charts showing a company's dealmaking activity since 2009, allowing quick identification potential partners - Partnering therapy focus revealed - Partnering activity since 2010 - number of deals per year - Full listing of partnering deals - Activity by deal type - Activity by industry sector - Activity by phase of development - Activity by technology type - Activity by therapeutic area - Comprehensive access to over 1,500 partnering deals as recorded at Current Agreement, together with contract documents if available - Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents - Understand the key deal terms the company has agreed in previous deals - Undertake due diligence to assess suitability of your proposed deal terms for partner companies Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Big biotech top 50 dealmaking activity Chapter 3 - Top big biotech deals by value Chapter 4 - Submitting Opportunities to Big biotech Chapter 5 - Forthcoming big biotech partnering events Chapter 6 - Big Biotech Company Profiles - 30 of the 50 companies - Acorda Therapeutics - Actavis - Actelion - Alexion Pharmaceuticals - Alkermes - Allergan - Amgen - Bavarian Nordic - Biocon - Biogen Idec - BioMarin Pharmaceuticals - Celgene - CSL - Cubist - Genmab - Gilead Sciences - Isis Pharmaceuticals - Jaxx Pharmaceuticals - LFB Group - Medivation - PDL BioPharma - Pharmacyclics - Questcor Pharmaceuticals - Regeneron Pharmaceuticals - Roche - Salix Pharmaceuticals - SciClone Pharmaceuticals - Seattle Genetics - Shire - Vertex Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/dxqgzt/top_50_big
BIIB: 423.57 (+1.46), VRTX: 132.85 (+0.65), SLXP: 172.96 (+0.15), AMGN: 169.10 (+0.64), ACOR: 33.34 (-1.33), ALKS: 62.60 (-0.24), PDLI: 7.07 (unch), AGN: 240.22 (+2.88), ISIS: 66.26 (-0.03), GILD: 104.18 (-1.02), ALXN: 188.19 (+1.41), SCLN: 8.99 (+0.04), REGN: 472.63 (+9.41), CELGZ: 2.87 (+0.04)
Monoclonal Antibodies Partnering Deals, Terms and Agreements 2010-2015
M2 - Thu Apr 16, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m7zvsb/monoclonal) has announced the addition of the "Monoclonal Antibodies Partnering Terms and Agreements" report to their offering. The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest monoclonal antibody deals announced in the healthcare sectors. This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since 2010 including financial terms where available including over 500 links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in monoclonal antibody dealmaking Chapter 3 - Leading monoclonal antibody deals Chapter 4 - Big pharma monoclonal antibody deals Chapter 5 - Big biotech monoclonal antibodies deals Chapter 6 - Monoclonal antibody contracts dealmaking directory Chapter 7 - Monoclonal antibody deals by individual technology type Chapter 8 - Monoclonal antibody partnering resource center Companies Mentioned - Partial List - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Servier - Shionogi - Takeda - Teva - Alexion Pharmaceuticals - Elan - Emergent BioSolutions - Galapagos - Genmab - LFB Group - Morphosys - Novo Nordisk - PDL BioPharma - Regeneron Pharmaceuticals - Seattle Genetics - Spectrum Pharmaceuticals - Swedish Orphan Biovitrum - ADMA Biologics - Alexion Pharmaceuticals - Amgen - AstraZeneca - Avecia Biologics - AVEO Pharmaceuticals - Biotest - Boehringer Ingelheim For more information visit http://www.researchandmarkets.com/research/m7zvsb/monoclonal
NVO: 56.37 (-0.17), EBS: 29.84 (-0.13), ADMA: 8.98 (-0.03), AVEO: 2.04 (+0.12), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), SPPI: 5.98 (+0.04), REGN: 472.63 (+9.41), PDLI: 7.07 (unch)
Alexion Pharmaceuticals Now #130 Largest Company, Surpassing Kroger
TheOnlineInvestor.com - Wed Apr 15, 3:38PM CDT
In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Alexion Pharmaceuticals Inc. has taken over the #130 spot from Kroger Co.
ALXN: 188.19 (+1.41)
Biotech Stock Roundup: Favorable Briefing Documents for MDCO's Kengreal, Alexion Soliris Label Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 15, 2:15PM CDT
The Medicines Co. (MDCO) was in the limelight with the company gearing up for an FDA advisory panel meeting.
BIIB: 423.57 (+1.46), VRTX: 132.85 (+0.65), GWPH: 113.04 (-0.05), MDCO: 27.84 (+0.25), ALXN: 188.19 (+1.41), TKMR: 18.38 (-0.14), AMGN: 169.10 (+0.64)
Alexion Up as Soliris Gains EU Nod for Label Updates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 4:00PM CDT
Alexion Pharmaceuticals, Inc. announced that the European Commission has approved updates to the EU label for Soliris.
CYTK: 7.29 (-0.09), ALXN: 188.19 (+1.41), ACOR: 33.34 (-1.33), AFFX: 12.57 (-0.13)
Alexion Announces Presentations at 2015 American Transplant Congress, Including Results from Studies Advancing the Understanding of Eculizumab (Soliris(R)) in Patients Undergoing Kidney Transplant
Business Wire - Mon Apr 13, 5:30AM CDT
--Study Underscoring the Benefit of Soliris in aHUS Patients With or Without History of Transplant also to be Presented--
ALXN: 188.19 (+1.41)
10 Largest Companies by Market Cap in Biotech
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 11, 2:02PM CDT
Source: Celgene Big bucks are being made in biotech. That's clear from the sizzling performance of the industry. If five years ago you had invested $1,000 each in the current 10 biggest biotechs in terms of market cap, you would now have over...
BIIB: 423.57 (+1.46), VRTX: 132.85 (+0.65), PCYC: 256.98 (-0.77), BMRN: 121.08 (-0.16), GILD: 104.18 (-1.02), INCY: 107.98 (-1.20), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), ABBV: 64.52 (+0.91), REGN: 472.63 (+9.41), CELG: 115.54 (+0.72)
Alexion Pharmaceuticals
at Investor's Business Daily - Fri Apr 10, 5:56PM CDT
Alexion Pharmaceuticals (ALXN) won European OK to update the label of its drug Soliris for paroxysmal nocturnal hemoglobinuria to include patients with no history of transfusion. Alexion stock rose 3% to 182.68.
ALXN: 188.19 (+1.41)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 423.57 (+1.46), SPHS: 0.82 (+0.01), ADMS: 17.62 (-0.21), TKMR: 18.38 (-0.14), CBYL: 7.02 (-0.38), HPTX: 45.96 (-0.18), QURE: 26.15 (-1.44), SHPG: 253.58 (+3.70), SRPT: 13.52 (+0.04), HZNP: 30.96 (+0.10), GALE: 1.39 (unch), JUNO: 55.72 (-0.68), ABBV: 64.52 (+0.91), CBMG: 32.14 (+2.21), ARNA: 4.47 (+0.01), EXEL: 3.12 (+0.05), ADXS: 22.18 (+0.10), PTLA: 38.48 (-0.47), BMY: 66.60 (-0.21), OCUL: 25.90 (-0.05), NVO: 56.37 (-0.17), DVA: 83.22 (+0.10), HALO: 16.03 (+0.15), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), ALXN: 188.19 (+1.41), NVS: 103.45 (-0.62)
Technical Analysis on Biotech Equities -- Achillion Pharma, Alexion Pharma, MEI Pharma, MiMedx, and RXi Pharma
PR Newswire - Fri Apr 10, 8:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
RXII: 0.70 (-0.01), ACHN: 10.01 (-0.13), ALXN: 188.19 (+1.41), MDXG: 10.21 (-0.17), MEIP: 2.08 (-0.16)
Updated label cleared in Europe for Alexion's Soliris
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 7:10AM CDT
ALXN: 188.19 (+1.41)
Alexion Receives Approval for Important Updates to the European Label for Soliris(R) (eculizumab)
Business Wire - Fri Apr 10, 1:00AM CDT
--Updated EU Label Includes New aHUS Data on Efficacy of Long-term Soliris Treatment and Risks Associated with Discontinuing Treatment
ALXN: 188.19 (+1.41)
Forget Google: 5 Top Stocks With Earnings Thursday
at Investor's Business Daily - Wed Apr 22, 6:31PM CDT
Tech titan Google (GOOGL) will make headlines with its quarterly earnings after the close on Thursday. But Google's growth is sluggish and the stock is lackluster. Check out these five stocks with better performance than the search giant, including...
AMZN: 389.80 (-1.38), PCYC: 256.98 (-0.77), MO: 52.12 (+0.02), ALK: 64.31 (-0.62), LUV: 42.85 (-0.18), SBUX: 48.33 (-0.04), GILD: 104.18 (-1.02), ALXN: 188.19 (+1.41), GM: 37.16 (unch), GOOGL: 549.18 (+6.26), ABBV: 64.52 (+0.91), PG: 83.09 (+0.01), MSFT: 42.99 (+0.36), DOW: 50.02 (+0.37)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 4:30PM CDT
CAM: 49.02 (+0.36), BBT: 38.87 (+0.21), LAZ: 56.56 (-0.08), JAH: 51.68 (-0.16), ASPS: 18.07 (+1.32), HSY: 98.33 (+0.31), CAB: 53.76 (-0.12), CFX: 48.68 (+0.12), FAF: 36.74 (+0.57), HP: 73.53 (+1.48), KKR: 23.37 (+0.21), AEP: 56.14 (+0.17), DNKN: 47.72 (+0.21), CLFD: 15.63 (+0.19), DAN: 21.57 (+0.18), ABBV: 64.52 (+0.91), CSL: 94.86 (+0.78), CAT: 84.87 (+0.95), BHE: 24.51 (-0.19), AVT: 45.49 (+0.28), IR: 67.49 (+0.29), COR: 48.82 (-0.57), ALK: 64.31 (-0.62), COL: 96.55 (+0.45), BKU: 33.64 (+0.12), BCC: 38.42 (-0.13), MJN: 98.92 (-1.00), IQNT: 18.03 (+0.28), ERIC: 12.70 (-0.09), DGX: 76.29 (+0.08), ALXN: 188.19 (+1.41), DOW: 50.02 (+0.37), DST: 116.35 (+0.44), MDP: 52.99 (-0.41), MMM: 164.67 (+0.67), GRA: 97.10 (+0.03), FCX: 20.57 (+0.34), CLI: 18.28 (-0.01), DHR: 85.25 (+0.05), FNB: 13.21 (+0.10), LUV: 42.85 (-0.18), DPS: 78.81 (-0.38), IVC: 19.80 (+0.24), GMT: 59.92 (+0.42), JNS: 17.93 (unch), DPZ: 99.80 (+0.40), DLX: 69.57 (+0.47), CMS: 35.07 (+0.15), LTM: 71.60 (+0.17), MDSO: 47.66 (+0.43), LLY: 72.30 (+0.09), BMS: 44.00 (+0.09), EQT: 87.29 (+0.85), MHO: 23.74 (-0.25), BTU: 4.87 (+0.06), GPK: 14.24 (+0.15), BAX: 70.38 (+0.33), EQM: 83.89 (+0.08), BEAV: 63.43 (-0.01), GM: 37.16 (unch), HUB.B: 110.19 (-0.19), JCI: 51.33 (+0.30)
Alexion reports tomorrow
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:18AM CDT
ALXN: 188.19 (+1.41)
Will Alexion's (ALXN) Soliris Drive Q1 Earnings Beat? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 4:10PM CDT
Alexion Pharmaceuticals, Inc. is scheduled to report first-quarter 2015 earnings results on Apr 23 before the opening bell.
BIIB: 423.57 (+1.46), IMGN: 9.96 (+0.01), ALXN: 188.19 (+1.41), ABBV: 64.52 (+0.91)
Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019 with Alexion Pharmaceuticals, Amgen, Celgene, F. Hoffmann- La Roche, GlaxoSmithKline & Incyte Dominating
PR Newswire Europe - Mon Apr 20, 10:13AM CDT
DUBLIN, Apr. 20, 2015 /PRNewswire/ --Research and Markets
ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), CELGZ: 2.87 (+0.04)
Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
M2 - Mon Apr 20, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w97ksb/global_acquired) has announced the addition of the "Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019" report to their offering. The Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29% over the period 2014-2019 Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS. Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price. According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups. Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population. Key Vendors - Alexion Pharmaceuticals - Amgen - Celgene - F. Hoffmann- La Roche - GlaxoSmithKline - Incyte Other Prominent Vendors - Cyclacel Pharmaceuticals - CTI Biopharma (Cell Therapeutics) - Eli Lilly - Gilead Sciences - Onconova Therapeutics - MebVax Therapeutics - Novartis - Sanofi - Shire Pharmaceuticals - S* Bio Pte For more information visit http://www.researchandmarkets.com/research/w9...l_acquired
CYCC: 0.94 (-0.03), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), ONTX: 2.48 (-0.05), LLY: 72.30 (+0.09), GSK: 46.57 (-0.67), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
Next Week In Biotech: Amgen, AbbVie, Biogen Earnings, UniQure CHMP, AAN Meeting
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
ABT: 48.35 (+1.23), BIIB: 423.57 (+1.46), NEO: 4.84 (-0.03), SGMO: 14.37 (-0.03), IMGN: 9.96 (+0.01), AMGN: 169.10 (+0.64), ILMN: 190.04 (-9.27), SVA: 5.06 (+0.10), BCLI: 4.29 (-0.09), ISRG: 516.93 (-29.80), BABY: 41.64 (+1.71), QURE: 26.15 (-1.44), NURO: 1.32 (-0.02), ABAX: 63.25 (-0.09), GWPH: 113.04 (-0.05), ALXN: 188.19 (+1.41), ABBV: 64.52 (+0.91), AMAG: 57.68 (+0.47), CAT: 84.87 (+0.95), MAA: 76.57 (+1.00), NVS: 103.45 (-0.62)
Top 50 Big Biotech Partnering and M&A Deal Trends Report 2015
M2 - Thu Apr 16, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxqgzt/top_50_big) has announced the addition of the "Top 50 Big Biotech Partnering and M&A Deal Trends" report to their offering. The Top 50 Big Biotech Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies. Top 50 Big Biotech Partnering and M&A Deal Trends provides the user with the following key benefits: - Detailed partnering activity profiles for each of the top 50 big biotech companies - Over 300 charts showing a company's dealmaking activity since 2009, allowing quick identification potential partners - Partnering therapy focus revealed - Partnering activity since 2010 - number of deals per year - Full listing of partnering deals - Activity by deal type - Activity by industry sector - Activity by phase of development - Activity by technology type - Activity by therapeutic area - Comprehensive access to over 1,500 partnering deals as recorded at Current Agreement, together with contract documents if available - Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents - Understand the key deal terms the company has agreed in previous deals - Undertake due diligence to assess suitability of your proposed deal terms for partner companies Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Big biotech top 50 dealmaking activity Chapter 3 - Top big biotech deals by value Chapter 4 - Submitting Opportunities to Big biotech Chapter 5 - Forthcoming big biotech partnering events Chapter 6 - Big Biotech Company Profiles - 30 of the 50 companies - Acorda Therapeutics - Actavis - Actelion - Alexion Pharmaceuticals - Alkermes - Allergan - Amgen - Bavarian Nordic - Biocon - Biogen Idec - BioMarin Pharmaceuticals - Celgene - CSL - Cubist - Genmab - Gilead Sciences - Isis Pharmaceuticals - Jaxx Pharmaceuticals - LFB Group - Medivation - PDL BioPharma - Pharmacyclics - Questcor Pharmaceuticals - Regeneron Pharmaceuticals - Roche - Salix Pharmaceuticals - SciClone Pharmaceuticals - Seattle Genetics - Shire - Vertex Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/dxqgzt/top_50_big
BIIB: 423.57 (+1.46), VRTX: 132.85 (+0.65), SLXP: 172.96 (+0.15), AMGN: 169.10 (+0.64), ACOR: 33.34 (-1.33), ALKS: 62.60 (-0.24), PDLI: 7.07 (unch), AGN: 240.22 (+2.88), ISIS: 66.26 (-0.03), GILD: 104.18 (-1.02), ALXN: 188.19 (+1.41), SCLN: 8.99 (+0.04), REGN: 472.63 (+9.41), CELGZ: 2.87 (+0.04)
Monoclonal Antibodies Partnering Deals, Terms and Agreements 2010-2015
M2 - Thu Apr 16, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m7zvsb/monoclonal) has announced the addition of the "Monoclonal Antibodies Partnering Terms and Agreements" report to their offering. The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest monoclonal antibody deals announced in the healthcare sectors. This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since 2010 including financial terms where available including over 500 links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in monoclonal antibody dealmaking Chapter 3 - Leading monoclonal antibody deals Chapter 4 - Big pharma monoclonal antibody deals Chapter 5 - Big biotech monoclonal antibodies deals Chapter 6 - Monoclonal antibody contracts dealmaking directory Chapter 7 - Monoclonal antibody deals by individual technology type Chapter 8 - Monoclonal antibody partnering resource center Companies Mentioned - Partial List - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Servier - Shionogi - Takeda - Teva - Alexion Pharmaceuticals - Elan - Emergent BioSolutions - Galapagos - Genmab - LFB Group - Morphosys - Novo Nordisk - PDL BioPharma - Regeneron Pharmaceuticals - Seattle Genetics - Spectrum Pharmaceuticals - Swedish Orphan Biovitrum - ADMA Biologics - Alexion Pharmaceuticals - Amgen - AstraZeneca - Avecia Biologics - AVEO Pharmaceuticals - Biotest - Boehringer Ingelheim For more information visit http://www.researchandmarkets.com/research/m7zvsb/monoclonal
NVO: 56.37 (-0.17), EBS: 29.84 (-0.13), ADMA: 8.98 (-0.03), AVEO: 2.04 (+0.12), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), SPPI: 5.98 (+0.04), REGN: 472.63 (+9.41), PDLI: 7.07 (unch)
Alexion Pharmaceuticals Now #130 Largest Company, Surpassing Kroger
TheOnlineInvestor.com - Wed Apr 15, 3:38PM CDT
In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Alexion Pharmaceuticals Inc. has taken over the #130 spot from Kroger Co.
ALXN: 188.19 (+1.41)
Biotech Stock Roundup: Favorable Briefing Documents for MDCO's Kengreal, Alexion Soliris Label Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 15, 2:15PM CDT
The Medicines Co. (MDCO) was in the limelight with the company gearing up for an FDA advisory panel meeting.
BIIB: 423.57 (+1.46), VRTX: 132.85 (+0.65), GWPH: 113.04 (-0.05), MDCO: 27.84 (+0.25), ALXN: 188.19 (+1.41), TKMR: 18.38 (-0.14), AMGN: 169.10 (+0.64)
Alexion Up as Soliris Gains EU Nod for Label Updates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 4:00PM CDT
Alexion Pharmaceuticals, Inc. announced that the European Commission has approved updates to the EU label for Soliris.
CYTK: 7.29 (-0.09), ALXN: 188.19 (+1.41), ACOR: 33.34 (-1.33), AFFX: 12.57 (-0.13)
Alexion Announces Presentations at 2015 American Transplant Congress, Including Results from Studies Advancing the Understanding of Eculizumab (Soliris(R)) in Patients Undergoing Kidney Transplant
Business Wire - Mon Apr 13, 5:30AM CDT
--Study Underscoring the Benefit of Soliris in aHUS Patients With or Without History of Transplant also to be Presented--
ALXN: 188.19 (+1.41)
10 Largest Companies by Market Cap in Biotech
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 11, 2:02PM CDT
Source: Celgene Big bucks are being made in biotech. That's clear from the sizzling performance of the industry. If five years ago you had invested $1,000 each in the current 10 biggest biotechs in terms of market cap, you would now have over...
BIIB: 423.57 (+1.46), VRTX: 132.85 (+0.65), PCYC: 256.98 (-0.77), BMRN: 121.08 (-0.16), GILD: 104.18 (-1.02), INCY: 107.98 (-1.20), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), ABBV: 64.52 (+0.91), REGN: 472.63 (+9.41), CELG: 115.54 (+0.72)
Alexion Pharmaceuticals
at Investor's Business Daily - Fri Apr 10, 5:56PM CDT
Alexion Pharmaceuticals (ALXN) won European OK to update the label of its drug Soliris for paroxysmal nocturnal hemoglobinuria to include patients with no history of transfusion. Alexion stock rose 3% to 182.68.
ALXN: 188.19 (+1.41)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 423.57 (+1.46), SPHS: 0.82 (+0.01), ADMS: 17.62 (-0.21), TKMR: 18.38 (-0.14), CBYL: 7.02 (-0.38), HPTX: 45.96 (-0.18), QURE: 26.15 (-1.44), SHPG: 253.58 (+3.70), SRPT: 13.52 (+0.04), HZNP: 30.96 (+0.10), GALE: 1.39 (unch), JUNO: 55.72 (-0.68), ABBV: 64.52 (+0.91), CBMG: 32.14 (+2.21), ARNA: 4.47 (+0.01), EXEL: 3.12 (+0.05), ADXS: 22.18 (+0.10), PTLA: 38.48 (-0.47), BMY: 66.60 (-0.21), OCUL: 25.90 (-0.05), NVO: 56.37 (-0.17), DVA: 83.22 (+0.10), HALO: 16.03 (+0.15), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), ALXN: 188.19 (+1.41), NVS: 103.45 (-0.62)
Technical Analysis on Biotech Equities -- Achillion Pharma, Alexion Pharma, MEI Pharma, MiMedx, and RXi Pharma
PR Newswire - Fri Apr 10, 8:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
RXII: 0.70 (-0.01), ACHN: 10.01 (-0.13), ALXN: 188.19 (+1.41), MDXG: 10.21 (-0.17), MEIP: 2.08 (-0.16)
Updated label cleared in Europe for Alexion's Soliris
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 7:10AM CDT
ALXN: 188.19 (+1.41)
Alexion Receives Approval for Important Updates to the European Label for Soliris(R) (eculizumab)
Business Wire - Fri Apr 10, 1:00AM CDT
--Updated EU Label Includes New aHUS Data on Efficacy of Long-term Soliris Treatment and Risks Associated with Discontinuing Treatment
ALXN: 188.19 (+1.41)
